The significance of detecting glucose transporter 1 and calretinin in serous effusions to differentiate between carcinoma cells and reactive mesothelial cells
Diagnostic Cytopathology. 2021;49(7):811-816 
Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: The utility of immunocytochemical panel in the differential diagnosis
Diagnostic Cytopathology. 2009;37(5):324-332
240 Immunocytochemistry with ten commercially available antibodies in adenocarcinoma cells, malignant or reactive mesothelial cells in serous effusions
Lung Cancer. 2006;54:S58
Benign Effusions
Serous Effusions. 2018;3-28
CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells
Human Pathology. 2016;58:123-127
The identification of mesothelial cells in sediments of serous effusions
Cancer. 1959;12(3):429-437
MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions
Human Pathology. 2016;47(1):104-108
Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry
Diagnostic Cytopathology. 2010;39(12):900-908
Immunocytochemical panel for distinguishing carcinoma cells from reactive mesothelial cells in pleural effusions
Cytopathology. 2008;19(4):212-217
Lectin microarrays differentiate carcinoma cells from reactive mesothelial cells in pleural effusions
Cytotechnology. 2012;65(3):355-362
